Company Focus
Icon
Latest Icon News
Pharmaceutical
As the world’s leading cancer research professionals arrived at the European Society for Medical Oncology (ESMO) Congress 2024 in Barcelona on Friday, they were given a reminder of some of the remaining challenges that lie ahead in their field. 13 September 2024
Related News
Insights
Company Spotlight
An ophthalmic gene therapy company aiming to restore and improve the vision of patients with a range of prevalent and rare retinal diseases that result in blindness.
Latest News & Features of interest to Icon
Biotechnology
Johnson & Johnson has announced data highlighting that Darzalex Faspro (daratumumab and hyaluronidase-fihj)-based regimens improve overall and sustained minimal residual disease (MRD) negativity rates and progression-free survival (PFS) in newly diagnosed multiple myeloma (NDMM), regardless of transplant status. 9 December 2024
Biotechnology
Dizal has announced the latest data from a pooled safety and efficacy analysis of DZD8586, a non-covalent blood-brain barrier (BBB) penetrant LYN/BTK dual inhibitor, in B-cell non-Hodgkin lymphoma (B-NHL). 9 December 2024
Biotechnology
After previously rejecting an application for this indication, the US Food and Drug Administration (FDA) has now accepted for review data from the MATINEE study to support the regulatory review process to obtain a new indication for Nucala (mepolizumab). 9 December 2024
Biotechnology
AbbVie has announced updated results from the Phase Ib/II EPCORE NHL-2 trial evaluating fixed-duration investigational epcoritamab, a CD3xCD20 bispecific T-cell-engaging antibody administered subcutaneously, plus lenalidomide and rituximab (R2) in relapsed or refractory (R/R) follicular lymphoma (FL). 9 December 2024
Biotechnology
Positive results from the AMPLIFY Phase III trial have shown that adding AstraZeneca’s Calquence (acalabrutinib) to venetoclax led to a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukaemia (CLL). 9 December 2024
Biosimilars
Germany’s Formycon has entered into a licensing and supply agreement with MS Pharma for the commercialization of FYB202, Formycon’s biosimilar to Johnson & Johnson’s Stelara (ustekinumab), in the Middle East and North Africa (MENA region). 9 December 2024
Pharmaceutical
Monday looks likely to be a tough day for BioAge Labs, a US biopharma developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. 9 December 2024
Biotechnology
Datopotamab deruxtecan (Dato-DXd) has been granted Breakthrough Therapy designation (BTD) by the US Food and Drug Administration (FDA) for the treatment of adult patients with lung cancer. 9 December 2024
Biotechnology
Positive new five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy (polatuzumab vedotin) in combination with MabThera/Rituxan (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL) were released on Sunday by Swiss pharma giant Roche. 9 December 2024
Latest In Brief for Icon
Biotechnology
The Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) for the treatment of early Alzheimer’s disease (AD). 5 December 2024
Latest Relevant Ones To Watch News
GE Healthcare has announced plans to acquire from Sumitomo Chemical the half of Nihon Medi-Physics (NMP) that it doesn’t own. 5 December 2024
3 December 2024
29 November 2024
26 November 2024
21 November 2024
19 November 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze